Fig. 3
Effect of oxyresveratrol (OR)-mediated mitogen-activated protein kinase (MAPK) inhibition on RANKL-induced osteoclast differentiation. pERK, pJNK, and pP38 levels in RAW 264.7 cells by western blotting. Levels of (a) pERK, (c) pP38, and (e) pJNK after treatment with RANKL and OR (100 nM, 1 μM, and 10 μM). Cells were harvested after 15, 240, and 30 min for pERK, pP38, and pJNK, respectively. Protein levels of (b) pERK, (d) pJNK, and (f) pP38. ERK, P38, and JNK were used as loading controls. Data are percentages versus RANKL (***p < 0.001, n = 3)